Zagociguat clinical trials
Also written CY6463 and IW-6463.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses zagociguat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Tisento Therapeutics (7)
Studies
Open first, then newest update. How each study uses zagociguat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)TerminatedPhase 2Tisento TherapeuticsNCT06961344Written as zagociguat 15mg
- A Phase 2b Study of Zagociguat in Patients With MELASCompletedPhase 2Tisento TherapeuticsNCT06402123Written as zagociguat 15mg
- A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular PathologyTerminatedPhase 2Tisento TherapeuticsNCT04798989Written as CY6463
- Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)TerminatedPhase 2Tisento TherapeuticsNCT04475549Written as IW-6463 Tablets
- A Study of IW-6463 in Healthy VolunteersCompletedPhase 1Tisento TherapeuticsNCT03856827Written as IW-6463
- IW-6463 Safety Study in Healthy Elderly SubjectsTerminatedPhase 1Tisento TherapeuticsNCT04240158Written as IW-6463
- Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable SchizophreniaCompletedPhase 1Tisento TherapeuticsNCT04972227Written as CY6463
Codes
What other systems call zagociguat · ClinicalTrials.gg INT016753
- UNII (FDA) H7KEN3O8AIZAGOCIGUATOne source FDA
- NCI Thesaurus C188581ZagociguatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H7KEN3O8AI | ZAGOCIGUAT | One source FDA |
| NCI Thesaurus | C188581 | Zagociguat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.